It builds on a portfolio of products used by the Ob/Gyn that currently includes our GELNIQUE(R) (oxybutynin chloride) gel treatment for overactive bladder (OAB) and FEMRING(R) (estradiol acetate) vaginal ring hormone replacement therapy …
Read more:
Watson Announces Agreement to Acquire U.S. Rights to Columbia …